In summary, our study demonstrated that AZD1390 alleviated ischemic brain injury in experimental stroke and attenuated the activation of microglia and neuroinflammation, which might attribute to the suppression of the NF‐κB signaling pathway through NEMO modification. The gene discussed is NFKB1; the disease is stroke disorder.